RARα is a regulatory factor for Am-80-induced cell growth inhibition of hematologic malignant cells

International Journal of Oncology

Volumn 31, Issue 2, 2007, Pages 397-404

  Jimi, Shiro ^a   Mashima, Kota ^c   Matsumoto, Taichi ^b   Hara, Shuji ^d   Suzumiya, Junji ^d   Tamura, Kazuo ^b  

^a FUKUOKA UNIVERSITY   (Japan)

^b FUKUOKA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c FUKUOKA UNIVERSITY HOSPITAL   (Japan)

^d Fukuoka University Chikushi Hospital   (Japan)

Author keywords

Am 80; Growth inhibition; Rar ; Tamibarotene; TGF culture

Indexed keywords

BENZOIC ACID DERIVATIVE; RETINOIC ACID RECEPTOR; RETINOIC ACID RECEPTOR ALPHA; RETINOID; TAMIBAROTENE; TETRALIN DERIVATIVE; TRANSFORMING GROWTH FACTOR BETA2;

APOPTOSIS; ARTICLE; BLOOD DISEASE; CELL PROLIFERATION; CELL STRAIN HL 60; CELL STRAIN K 562; DOSE RESPONSE; HUMAN; METABOLISM; PHOSPHORYLATION; PHYSIOLOGY; TUMOR CELL LINE; TUMOR SUPPRESSOR GENE;

APOPTOSIS; BENZOATES; CELL LINE, TUMOR; CELL PROLIFERATION; DOSE-RESPONSE RELATIONSHIP, DRUG; GENES, TUMOR SUPPRESSOR; HEMATOLOGIC NEOPLASMS; HL-60 CELLS; HUMANS; K562 CELLS; PHOSPHORYLATION; RECEPTORS, RETINOIC ACID; RETINOIDS; TETRAHYDRONAPHTHALENES; TRANSFORMING GROWTH FACTOR BETA2;

EID: 35148865782     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.31.2.397     Document Type: Article

References (34)

1. Oren T, Sher JA and Evans T: Hematopoiesis and retinoids: development and disease. Leuk Lymphoma 44: 1881-1891, 2003.
2. Sonneveld E and van der Saag PT: Metabolism of retinoic acid: implications for development and cancer. Int J Vitam Nutr Res 68: 404-410, 1998. (Pubitemid 28552004)
3. Pemrick SM, Lucas DA and Grippo JF: The retinoid receptors. Leukemia 8: 1797-1806, 1994.
4. + erythroid progenitor cells. Blood 87: 1728-1736, 1996.
5. Huang ME, Ye YC, Chen SR, Chai JR, Lu JX, Zhoa L, Gu LJ and Wang ZY: Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia. Blood 72: 567-572, 1988.
6. Chen SJ, Wang ZY and Chen Z: Acute promyelocytic leukemia: from clinic to molecular biology. Stem Cells 13: 22-31, 1995.
7. Mandelli F, Diverio D, Avvisati G, Luciano A, Barbui T, Bernasconi C, Broccia G, Cerri R, Falda M, Fioritoni G, Leoni F, Liso V, Petti MC, Rodeghiero F, Saglio G, Vegna ML, Visani G, Jehn U, Willemze R, Muus P, Pelicci PG, Biondi A and Lo Coco F: Molecular remission in PML/RAR alphapositive acute promyelocytic leukemia by combined all-trans retinoic acid and idarubicin (AIDA) therapy. Gruppo Italiano- Malattie Ematologiche Maligne dell'Adulto and Associazione Italiana di Ematologia ed Oncologia Pediatrica Cooperative Groups. Blood 90: 1014-1021, 1997.
8. Chen Z, Guidez F, Rousselot P, Agadir A, Chen SJ, Wang ZY, Degos L, Zelent A, Waxman S and Chomienne C: PLZF-RAR alpha fusion proteins generated from the variant t(11;17) (q23;q21) translocation in acute promyelocytic leukemia inhibit ligand-dependent transactivation of wild-type retinoic acid receptors. Proc Natl Acad Sci USA 91: 1178-1182, 1994.
9. Hu ZB, Ma W, Uphoff CC, Lanotte M and Drexler HG: Modulation of gene expression in the acute promyelocytic leukemia cell line NB4. Leukemia 7: 1817-1823, 1993.
10. Miller WH Jr, Kakizuka A, Frankel SR, Warrell RP Jr, De Blasio A, Levine K, Evans RM and Dmitrovsky E: Reverse transcription polymerase chain reaction for the rearranged retinoic acid receptor alpha clarifies diagnosis and detects minimal residual disease in acute promyelocytic leukemia. Proc Natl Acad Sci USA 89: 2694-2698, 1992.
11. Fenaux P, Wang ZZ and Degos L: Treatment of acute promyelocytic leukemia by retinoids. Curr Top Microbiol Immunol 313: 101-128, 2007.
12. 3 combination yields a high quality remission and survival in newly diagnosed acute promyelocytic leukemia. Proc Natl Acad Sci USA 101: 5328-5335, 2004.
13. Fenaux P, Chevret S, Guerci A, Fegueux N, Dombret H, Thomas X, Sanz M, Link H, Maloisel F, Gardin C, Bordessoule D, Stoppa AM, Sadoun A, Muus P, Wandt H, Mineur P, Whittaker JA, Fey M, Daniel MT, Castaigne S and Degos L: Long-term follow-up confirms the benefit of all-trans retinoic acid in acute promyelocytic leukemia. European APL group. Leukemia 14: 1371-1377, 2000.
14. Wang Z, Sun G, Shen Z, Chen S and Chen Z: Differentiation therapy for acute promyelocytic leukemia with all-trans retinoic acid: 10-year experience of its clinical application. Chin Med J 112: 963-967, 1999.
15. Zhou DC, Hallam SJ, Lee SJ, Klein RS, Wiernik PH, Tallman MS and Gallagher RE: Constitutive expression of cellular retinoic acid binding protein II and lack of correlation with sensitivity to all-trans retinoic acid in acute promyelocytic leukemia cells. Cancer Res 58: 5770-5776, 1998.
16. Cornic M, Delva L, Castaigne S, Lefebvre P, Balitrand N, Degos L and Chomienne C: In vitro all-trans retinoic acid (ATRA) sensitivity and cellular retinoic acid binding protein (CRABP) levels in relapse leukemic cells after remission induction by ATRA in acute promyelocytic leukemia. Leukemia 8: 914-917, 1994.
17. Kagechika H, Kawachi E, Hashimoto Y, Himi T and Shudo K: Retinobenzoic acids. 1. Structure-activity relationships of aromatic amides with retinoidal activity. J Med Chem 31: 2182-2192, 1988.
18. Hashimoto Y, Kagechika H, Kawachi E, Fukasawa H, Saito G and Shudo K: Correlation of differentiation-inducing activity of retinoids on human leukemia cell lines HL-60 and NB4. J Cancer Res Clin Oncol 121: 696-698, 1995.
19. Tamura K, Kagechika H, Hashimoto Y, Shudo K, Ohsugi K and Ide H: Synthetic retinoids, retinobenzoic acids, Am80, Am580 and Ch55 regulate morphogenesis in chick limb bud. Cell Differ Dev 32: 17-26, 1990.
20. Okuno M, Kojima S, Matsushima-Nishiwaki R, Tsurumi H, Muto Y, Friedman SL and Moriwaki H: Retinoids in cancer chemoprevention. Curr Cancer Drug Targets 4: 285-298, 2004.
21. Mehta K, McQueen T, Neamati N, Collins S and Andreeff M: Activation of retinoid receptors RAR alpha and RXR alpha induces differentiation and apoptosis, respectively, in HL-60 cells. Cell Growth Differ 7: 179-186, 1996. (Pubitemid 26049826)
22. Mueller BU, Pabst T, Fos J, Petkovic V, Fey MF, Asou N, Buergi U and Tenen DG: ATRA resolves the differentiation block in t(15;17) acute myeloid leukemia by restoring PU.1 expression. Blood 107: 3330-3338, 2006.
23. Altucci L, Rossin A, Raffelsberger W, Reitmair A, Chomienne C and Gronemeyer H: Retinoic acid-induced apoptosis in leukemia cells is mediated by paracrine action of tumor-selective death ligand TRAIL. Nat Med 7: 680-686, 2001. (Pubitemid 32588023)
24. Shiohara M, Dawson MI, Hobbs PD, Sawai N, Higuchi T, Koike K, Komiyama A and Koeffler HP: Effects of novel RAR-and RXR-selective retinoids on myeloid leukemic proliferation and differentiation in vitro. Blood 93: 2057-2066, 1999.
25. Nagy L, Thomazy VA, Shipley GL, Fesus L, Lamph W, Heyman RA, Chandraratna RA and Davies PJ: Activation of retinoid X receptors induces apoptosis in HL-60 cell lines. Mol Cell Biol 15: 3540-3551, 1995.
26. Dawson MI, Chao WR, Pine P, et al: Correlation of retinoid binding affinity to retinoic acid receptor alpha with retinoid inhibition of growth of estrogen receptor-positive MCF-7 mammary carcinoma cells. Cancer Res 55: 4446-4451, 1995.
27. Miyazono K, Suzuki H and Imamura T: Regulation of TGF-beta signaling and its roles in progression of tumors. Cancer Sci 94: 230-234, 2003. (Pubitemid 36575887)
28. Falk LA, De Benedetti F, Lohrey N, Birchenall-Roberts MC, Ellingsworth LW, Faltynek CR and Ruscetti FW: Induction of transforming growth factor-beta 1 (TGF-beta 1), receptor expression and TGF-beta 1 protein production in retinoic acid-treated HL-60 cells: possible TGF-beta 1-mediated autocrine inhibition. Blood 77: 1248-1255, 1991.
29. Taipale J, Matikainen S, Hurme M and Keski-Oja J: Induction of transforming growth factor beta 1 and its receptor expression during myeloid leukemia cell differentiation. Cell Growth Differ 5: 1309-1319, 1994. (Pubitemid 24381519)
30. Han GR, Dohi DF, Lee HY, Rajah R, Walsh GL, Hong WK, Cohen P and Kurie JM: All-trans-retinoic acid increases transforming growth factor-beta2 and insulin-like growth factor binding protein-3 expression through a retinoic acid receptor-alpha-dependent signaling pathway. J Biol Chem 272: 13711-13716, 1997.
31. Sato Y, Okada F, Abe M, Seguchi T, Kuwano M, Sato S, Furuya A, Hanai N and Tamaoki T: The mechanism for the activation of latent TGF-beta during co-culture of endothelial cells and smooth muscle cells: cell-type specific targeting of latent TGF-beta to smooth muscle cells. J Cell Biol 123: 1249-1254, 1993.
32. Ribeiro SM, Poczatek M, Schultz-Cherry S, Villain M and Murphy-Ullrich JE: The activation sequence of thrombospondin- 1 interacts with the latency-associated peptide to regulate activation of latent transforming growth factor-beta. J Biol Chem 274: 13586-13593, 1999. (Pubitemid 129518577)
33. Heldin CH, Miyazono K and ten Dijke P: TGF-beta signalling from cell membrane to nucleus through SMAD proteins. Nature 390: 465-471, 1997. (Pubitemid 28013118)
34. Cordenonsi M, Dupont S, Maretto S, Insinga A, Imbriano C and Piccolo S: Links between tumor suppressors: p53 is required for TGF-beta gene responses by cooperating with Smads. Cell 113: 301-314, 2003. (Pubitemid 36556113)